S485
Clinical - Gynaecological
ESTRO 2026
Results: From February 2021 to December 2021, 33 patients were enrolled (stage IB3-IIIC), with a mean age of 57.24 ± 7.5years. During CCRT, incidence of hematologic toxicities were G1 4(12.1%), G2 12(36.4%), G3 14(42.4%), and G4 3(9%). With the increased delivered dose, the mean CT values of the sacrococcyx, hip bone and lumbar vertebra areas were gradually decreased from the 0th to 25th fractions, especially for the sacrococcyx and hip bone areas (p<0.001). Correlation analysis showed Δ CT10 (changes from 0th to 10th) in the sacrococcyx and hip bone areas were significantly correlated with the mean delivered dose respectively (sacrococcyx: r=0.29, p=0.024. hip bone: r=0.386, p=0.003). Multivariate analysis identified that Δ CT10 in the sacrococcyx area is an independent predictor for G3-4 hematologic toxicity after EBRT (p=0.04). ROC curve showed Δ CT10 in the sacrococcyx area could predict the occurrence of G3-4 hematologic toxicity during CCRT, with an AUC of 0.734 (p=0.027), sensitivity of 83.3%, and specificity of 71.4%. Conclusion: For cervical cancer patients undergoing radical CCRT, the mean CT values in plevic bone areas were significantly decreased with the increased delivered radiation dose during CCRT. Δ CT10 in the sacrococcyx area is an independent predictor for G3-4 hematologic toxicity during CCRT. References: Ma S, Wang J, Han Y, et al. Platinum single- agent vs. platinum-based doublet agent concurrent chemoradiotherapy for locally advanced cervical cancer: A meta-analysis of randomized controlled trials[J]. Gynecol Oncol, 2019, 154(1): 246-252.Zhu J, Zhang Z, Bian D, et al. Weekly versus triweekly cisplatin-based concurrent chemoradiotherapy in the treatment of locally advanced cervical carcinoma: An updated meta-analysis based on randomized controlled trials[J]. Medicine (Baltimore), 2020, 99(1): e18663.Zhou P, Zhang Y, Luo S, et al. Pelvic bone marrow sparing radiotherapy
for cervical cancer: A systematic review and meta-analysis[J]. Radiother Oncol, 2021, 165: 103-118. Keywords: hematologic toxicity; CT value
Digital Poster Highlight 4729
Metastasis-Directed Radiotherapy in Oligometastatic Gynecologic Cancers Libe Del Castillo, David Büchser, Alfonso Gomez de iturriaga, Elsira Boveda, Roberto Ortiz de zarate, Andere Frias, Fernan Suarez, Olga Del Hoyo, Iratxe Ratón, Carlos Mascarell, Ana Hompanera, Eluska Iruarrizaga, Irma Muruzabal, Amanda Flaquer, Teresa Espina, Veronica Cañon, Alba Gonzalez, Jon Cacicedo Oncología Radioterápica, Hospital Universitario de Cruces, Bilbao, Spain Purpose/Objective: To evaluate the efficacy and toxicity of high- dose radiotherapy in patients with recurrent or oligometastatic gynecologic cancers, including ovarian, endometrial, cervical, and vaginal cancers treated at our hospital. Material/Methods: Retrospective, single-center study. The primary endpoint was the local control (LC) rate of treated lesions, while secondary endpoints included progression-free survival (PFS), cancer-specific survival (CSS), and treatment-related toxicity. Toxicity was assessed using the CTCAE v.5 (Common Terminology Criteria for Adverse Events). A descriptive analysis of baseline population characteristics was performed using descriptive statistics. Survival was evaluated using Kaplan-Meier curves. Cumulative incidence was used to describe the occurrence of toxicities during follow-up. Results: Data were collected from 47 patients diagnosed with oligometastatic gynecologic cancer treated between 2017 and 2025. Median follow-up was 22 months (IQR 25–75 9.32). A total of 92 oligometastatic lesions were treated, of which 57.4% were nodal
Made with FlippingBook - Share PDF online